Allergan Settles Botox Off-Label Claims For $600M

By Abigail Rubenstein

Law360, New York (September 01, 2010, 3:01 PM ET) -- Allergan Inc. reached a $600 million settlement with the U.S. Department of Justice on Wednesday to resolve criminal and civil claims stemming from the company's marketing of off-label uses for its blockbuster wrinkle-treating drug Botox.

Allergan has agreed to plead guilty to a misdemeanor misbranding charge and will cough up $375 million for a criminal fine and forfeiture, as well as $225 million to fund a civil settlement with the federal government and several states. The global settlement must be approved by the U.S. District Court...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles